Maximum Dose of Ramipril in Adults
The maximum dose of ramipril in adults is 20 mg per day for hypertension and 10 mg per day (5 mg twice daily) for heart failure post-myocardial infarction. 1
Dosing by Indication
Hypertension
- Maximum dose: 20 mg daily 1
- Initial dose: 2.5 mg once daily
- Usual maintenance range: 2.5-20 mg per day, administered as a single dose or in two equally divided doses
- If antihypertensive effect diminishes toward the end of the dosing interval with once-daily dosing, consider increasing the dose or switching to twice-daily administration 1
The 2022 ACC/AHA/HFSA Heart Failure Guidelines list ramipril with a target dose of 10 mg once daily for heart failure with reduced ejection fraction 2, though the FDA label permits up to 20 mg daily for hypertension specifically 1.
Heart Failure Post-Myocardial Infarction
- Maximum dose: 10 mg per day (5 mg twice daily) 1
- Initial dose: 2.5 mg twice daily (or 1.25 mg twice daily if hypotension occurs)
- Target dose: 5 mg twice daily
- Titrate upward over approximately 3-week intervals as tolerated 1
Special Populations Requiring Dose Adjustment
Renal Impairment
For patients with creatinine clearance ≤40 mL/min, maximum doses are reduced 1:
Hypertension with renal impairment:
- Initial: 1.25 mg once daily
- Maximum: 5 mg total daily dose 1
Heart failure with renal impairment:
- Initial: 1.25 mg once daily
- May increase to 1.25 mg twice daily
- Maximum: 2.5 mg twice daily 1
Volume Depletion or Renal Artery Stenosis
- Start at 1.25 mg once daily regardless of indication
- Titrate according to blood pressure response 1
Important Clinical Considerations
Titration is critical: The 2022 ACC/AHA/HFSA guidelines emphasize titrating to target doses shown efficacious in randomized controlled trials to reduce cardiovascular mortality and heart failure hospitalizations 2. Titration can occur as frequently as every 1-2 weeks depending on symptoms, vital signs, and laboratory findings 2.
Research context: While one study explored ramipril doses up to 20 mg daily in chronic nephropathies 3, this represents investigational use beyond standard FDA-approved maximum dosing for heart failure indications. The FDA-approved maximum remains the standard of care.